Document is current
Any future updates will be listed below
-
Authors
Gunnarsdottir, Frida Björk
Bendahl, Pär-Ola
Johansson, Alexandra
Benfeitas, Rui
Rydén, Lisa
Bergenfelz, Caroline
Larsson, Anna-Maria
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01322893 at ClinicalTrials.govDocuments that mention this clinical trial
Serum immuno-oncology markers carry independent prognostic information in patients with newly diagnosed metastatic breast cancer, from a prospective observational study
https://doi.org/10.1186/s13058-023-01631-6
-
Funding
Funding for this research was provided by:
Lund University Medical Faculty Foundation
Gyllenstiernska Krapperupsstiftelsen
Gunnar Nilssons Cancerstiftelse
Allmänna Sjukhusets i Malmö Stiftelse för Bekämpande av Cancer
Fru Berta Kamprads Stiftelse
governmental funding for clinical research , Sweden
Lund University
- License Information
-
More Information
Article History
Received: 20 December 2022
Accepted: 2 March 2023
First Online: 21 March 2023
Declarations
:
: The study was approved by the Ethics Committee at Lund University, Lund, Sweden (LU. 2010/135). All included patients provided written informed consent for participation. The research was performed in accordance with the declaration of Helsinki.
: All included patients provided written informed consent for publication.
: RB was an employee at NBIS at the time of data analyses. RB is currently an employee of Chiesi Farmaceutici S.p.A. and does not hold Chiesi Farmaceutici S.p.A. stocks or equity shares. Chiesi Farmaceutici S.p.A. was not involved with the current study. FBG was an employee at Lund University at the time of data analyses and drafting the manuscript. FBG is currently an employee at Alligator Bioscience and does not hold Alligator Bioscience stocks or equity shares, and Alligator Bioscience was not involved with the current study. All other authors have no competing interests.
